Drug lookup
Drug reference

Tolcapone

COMT Inhibitor · Antiparkinsonian

COMT InhibitorAntiparkinsonian
CDSCO approvedSchedule H
EXCRETION
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Toxicity in animal studies. Use only if potential benefit outweighs risk.
FDA category + note
Top interactionssee all 12
  • DextropropoxypheneSevereDatabaseDDInter
  • IsocarboxazidSevereDatabaseDDInter
  • LeflunomideSevereDatabaseDDInter
  • LinezolidSevereDatabaseDDInter

Mechanism

Tolcapone prevents the peripheral breakdown of levodopa by inhibiting catechol-O-methyltransferase (COMT). This action increases the bioavailability of levodopa, allowing a greater amount to reach the brain where it can be converted to dopamine.

Indications

Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ‘end-of-dose’ motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase is inappropriate (under expert supervision)Parkinson's disease (adjunct to L-DOPA)Adjunctive PD therapy given with each dose of levodopa, for "wearing-off"Used as an adjuvant to levodopa-carbidopa for advanced and fluctuating Parkinson's disease (reserved for those not responding to entacapone in some regions due to safety concerns)

Dosing

Adult
100 mg 3 times a day, continuing beyond 3 weeks only if substantial improvement, leave 6 hours between each dose.
Renal adjustment
Caution if eGFR less than 30 mL/minute/1.73 m2.
Hepatic adjustment
Avoid in severe hepatic impairment. Consider dose reduction in moderate hepatic impairment.
Max dose
200 mg per dose (max 600 mg daily)

Pharmacokinetics

Duration
relatively long duration of action

Contraindications

  • Phaeochromocytoma
  • Previous history of hyperthermia
  • Previous history of neuroleptic malignant syndrome
  • Previous history of rhabdomyolysis
  • Severe dyskinesia
  • Severe hepatic impairment
  • Re-introduction after discontinuation due to abnormal liver function tests or symptoms of liver disorder
  • Acute fatal hepatitis (in some regions)
  • Rhabdomyolysis (in some regions)

Side effects

Common
Appetite decreasedChest painConfusionConstipationDiarrhoeaDizzinessDrowsinessDry mouthGastrointestinal discomfortHallucinationHeadacheHyperhidrosisInfluenza like illnessMovement disordersNauseaPostural hypotensionSleep disordersSyncopeUpper respiratory tract infectionUrine discolourationVomitingorthostatic hypotensionvivid dreamshallucinationsyellow-orange discolouration of urinedyskinesia
Serious
  • Hepatocellular injury
  • Potentially life-threatening hepatotoxicity including fulminant hepatitis
  • Eating disorders
  • Neuroleptic malignant syndrome (reported on dose reduction or withdrawal)
  • Pathological gambling
  • Psychiatric disorders
  • Sexual dysfunction
  • hepatotoxicity
  • fulminant hepatic failure
  • acute fatal hepatitis
  • rhabdomyolysis

Pregnancy & lactation

Pregnancy

Toxicity in animal studies. Use only if potential benefit outweighs risk.

Lactation

Avoid; present in milk in animal studies.

Drug interactions

Dextropropoxyphene
Severe
Database

Clinical effect not specified

Source: DDInter

Isocarboxazid
Severe
Database

Clinical effect not specified

Source: DDInter

Leflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Linezolid
Severe
Database

Clinical effect not specified

Source: DDInter

Lomitapide
Severe
Database

Clinical effect not specified

Source: DDInter

Methylene Blue
Severe
Database

Clinical effect not specified

Source: DDInter

Mipomersen
Severe
Database

Clinical effect not specified

Source: DDInter

Pexidartinib
Severe
Database

Clinical effect not specified

Source: DDInter

Phenelzine
Severe
Database

Clinical effect not specified

Source: DDInter

Procarbazine
Severe
Database

Clinical effect not specified

Source: DDInter

Sodium Oxybate
Severe
Database

Clinical effect not specified

Source: DDInter

Teriflunomide
Severe
Database

Clinical effect not specified

Source: DDInter

Related guidelines

Other COMT Inhibitor drugs

Ask House about Tolcapone

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team